Table 1 |
||
|
Recommended Action Items |
||
| ACTION ITEM |
RELATIVE COST |
RELATIVE IMPORTANCE |
|
|
||
| 1. Mapping |
||
| Updating country maps |
High/Moderate |
High |
| RAPLOA implementation |
Low |
High |
| 2. Pathogenesis and Clinical Aspects |
||
| Field case studies |
||
| Serial sampling (blood, CSF) |
Moderate |
High |
| Quick response (telephone system) |
Moderate |
High |
| Better clinical definition |
Low |
High |
| Improve data forms etc. |
Low |
High |
| Analysis of evolution of clinical picture to identify potential early warning signs |
Low |
High |
| Research on HPCs |
||
| Pathological specimens (with blood/serological correlates) |
Moderate |
High |
| Utility as early warning sign for PLERM |
Moderate |
High |
| Reliability of application by CDDs & community health workers |
Low |
High |
| Support Local Loiasis Technical Advisor |
High |
High |
| Hospital studies (more sophisticated sampling/testing) |
Moderate |
High |
| Population studies |
||
| Mdr1 and other genetic studies |
High |
Low |
| Food and alcohol toxicity surveys |
Moderate |
Moderate |
| Post-mortem studies |
||
| Core samples |
Low |
High |
| Immunohistology etc on AFIP/Marc Wéry samples |
Low |
High |
| Conjunctival samples |
Moderate |
Moderate |
| 3. Epidemiologic Aspects |
||
| Use of GIS software to map SAE cases |
Low |
High |
| Support epidemiologist specialized in cluster phenomena |
High |
High |
| Research on RAPLOA techniques applied at individual level |
Low |
High |
| 4. Pre-Treatment Approaches for L. loa endemic areas |
||
| Explore existing drugs with potential efficacy against L. loa |
Moderate |
High |
| Albendazole – repeated doses |
Moderate |
Moderate |
| Wolbachia (follow developments and respond where appropriate) |
(Low) |
(High) |
| Steroids (hospital study) |
Moderate |
Moderate |
| List of co-substrates for PGP and CYP3A4 potentially used locally |
Low |
Moderate |
| 5. Animal Models |
||
| Primates in Cameroon |
||
| To eventually lead to new therapies |
High |
(Pending)) |
| To study pathogenesis |
High |
Low |
| Mouse (should be secondary to primate studies) |
Moderate |
(Controversial) |
| Dog (unlikely to be comparable) |
High |
Low |
| In vitro studies (already being done at NIH) |
(High) |
(Medium) |
| 6. SAE management improvement / best care methodology |
||
| Improve SAE surveillance & reporting system |
Low |
High |
| Validation of activities, training, surveillance system |
Low |
High |
| Development & assessment of risk management models (incl. for LF) |
Low |
High |
| Education & counseling materials guided by community-based research |
Low |
High |
| Simple algorithm card for recognition, referral & management |
Low |
High |
| 7. Support research addressing expansion of programs to LF areas |
Low |
High |
|
|
||
|
Scientific Working Group on Serious Adverse Events in Loa Loa endemic areas Filaria Journal 2003 2(Suppl 1):S2 doi:10.1186/1475-2883-2-S1-S2 |
||
